American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1354)
  10. Hematologic Malignancies, Division of (1282)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2584)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6402)
  2. Solid Tumor Oncology Division (5540)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1638)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (291)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8707)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (10)

More Publications

Results (9183)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC)
    Meeting Abstract

    Frank, S. J.; Busse, P.; Rosenthal, D. I.; Hernandez, M.; Swanson, D. M.; Garden, A. S.; Sturgis, E. M.; Ferrarotto, R.; Gunn, G. B.; Patel, S. H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma
    Meeting Abstract

    Burton, E. M.; Wani, K. M.; Milton, D. R.; Segura, R. L.; Tetzlaff, M.; Ross, M. I.; Postow, M. A.; Glitza, I. C.; Wong, M. K. K.; Diab, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)
    Meeting Abstract

    Beltran, H.; Johnson, M. L.; Jain, P.; Schenk, E. L.; Sanborn, R. E.; Thompson, J. R.; Dowlati, A.; Mamdani, H.; Aggarwal, R. R.; Anand, B. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2-breast cancer (BC) cohorts of EV-202
    Meeting Abstract

    Giordano, A.; Awan, A. A. A.; Bruce, J. Y.; Rugo, H. S.; Diamond, J. R.; Novik, Y.; Baranda, J. C.; Muro, K.; Ono, M.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8α/β coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors
    Meeting Abstract

    Mitchell, S.; Khan, B.; Payumo, F.; Chiorean, E. G.; Gahvari, Z.; Hecht, J. R.; Hurwitz, M. E.; Leidner, R.; Lenz, H. J.; Pelster, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade
    Meeting Abstract

    Ricciuti, B.; Gariazzo, E.; Gorria, T.; Thummalapalli, R.; Citarella, F.; Gandhi, M. M.; Elkrief, A.; Pecci, F.; Alessi, J. V. M.; Di Federico, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Meeting Abstract

    Funt, S. A.; Grivas, P.; Gao, X.; Vaena, D. A.; Zhang, T.; Milowsky, M. I.; Rao, M.; Liu, H.; Tipton, K.; An, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)
    Meeting Abstract

    Winter, A. M.; Bharadwaj, S.; Herrera, A. F.; Iragavarapu, C.; Mirza, S.; Palomba, M. L.; Patel, S. S.; Gharibo, M. M.; Bernasconi, D.; Krimmel, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup
    Meeting Abstract

    Cohen, A. D.; Voorhees, P. M.; Martin, T. G.; Lesokhin, A. M.; Hillengass, J.; Kaufman, J. L.; Schecter, J. M.; De Braganca, K. C.; Varsos, H.; Corsale, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008
    Meeting Abstract

    Braunstein, L. Z.; Mitchell, M.; Bandos, H.; Sikov, W. M.; Khan, A. J.; Chen, P. Y.; Ganz, P. A.; Jagsi, R.; White, J. R.; Cecchini, R. S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save